{"id":"W2015354352","doi":"10.1586/14737140.5.6.1001","title":"Antisense oligodeoxynucleotide therapy for bladder cancer: recent advances and future prospects","year":2005,"lang":"en","type":"review","venue":"Expert Review of Anticancer Therapy","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Bladder cancer; Antisense therapy; Genetic enhancement; Cancer research; Cancer; Radiation therapy; Cancer therapy; Targeted therapy; Chemotherapeutic drugs; Internal medicine; Gene; Biology; Oligonucleotide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002751158,0.001009256,0.00460639,0.0001480156,0.0001219297,0.00002791427,0.0002735838,0.000294289,0.001081451],"category_scores_gemma":[0.00002208052,0.0006362685,0.001019409,0.000473326,0.0002297049,0.0001550035,0.00003342306,0.0002888783,0.000006556384],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002160923,"about_ca_system_score_gemma":0.0009518851,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002572942,"about_ca_topic_score_gemma":0.000008724046,"domain_scores_codex":[0.9965176,0.0001403809,0.001217851,0.0009940933,0.0005434299,0.000586618],"domain_scores_gemma":[0.9976318,0.0001232693,0.0007802323,0.000846995,0.0003619881,0.0002557385],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002404635,0.0003170135,0.0000156138,0.0451697,0.001216743,0.000008471058,0.0001085577,8.602919e-9,0.000008754468,0.0000476399,0.008012547,0.9448545],"study_design_scores_gemma":[0.002629837,0.0008578109,0.00002154511,0.07382209,0.0007874293,0.00007471948,0.00001586393,5.9329e-7,0.00009653801,0.00001521591,0.92113,0.0005483775],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000004274224,0.9865229,0.000008135443,0.003376516,0.0008951128,0.008239635,0.0002635671,0.00007336798,0.0006165283],"genre_scores_gemma":[7.843056e-7,0.9847044,0.001455552,0.006294875,0.004534023,0.002431299,0.0001198513,0.0002181272,0.0002410807],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9443061,"threshold_uncertainty_score":0.9998317,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04421512318308846,"score_gpt":0.416129422003612,"score_spread":0.3719142988205235,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}